TGFB1 and neoplasm: When TGF-β acts as a tumor promotor, it suppresses both the innate and adaptive immune systems and enhances tumor cell proliferation, migration and invasion, which collectively impact drug resistance and tumor escape, and undermine a clinical response to anticancer therapy (3).